Published in Medical Letter on the CDC and FDA, February 15th, 2004
Seborrheic dermatitis is a chronic inflammatory skin condition characterized by a red, scaly, itchy rash primarily occurring on the face, scalp, hairline, eyebrows, and trunk. Results determined that Sebazole is effective in the treatment of facial seborrheic dermatitis with a once-daily treatment regimen of only 2 weeks.
The two blinded placebo controlled phase III trials enrolled more than 900 patients in approximately 50 centers in the United States and Europe. Each study compared the safety and efficacy of the following treatment arms: Sebazole...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.